Abstract: A method of managing an online support group to increase the odds that users will attain their wellness goals is disclosed. A request from a user to join a support group is received. A preference of the user with respect to a type of the support group is received. The support group is selected from a plurality of support groups based on the preference of the user and a preference of a member of the support group. Based on an acceptance by the user of an option to join the support group, the plurality of support groups is reorganized.

Abstract: A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells; and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.

Abstract: A method of managing an online support group to increase the odds that users will attain their wellness goals is disclosed. A request from a user to join a support group is received. A preference of the user with respect to a type of the support group is received. The support group is selected from a plurality of support groups based on the preference of the user and a preference of a member of the support group. Based on an acceptance by the user of an option to join the support group, the plurality of support groups is reorganized.

Abstract: The invention relates to apolypeptide capable of binding to TGF-? for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-?, wherein said polypeptide is capable of inhibiting the interaction of TGF-? with the receptor CLPTM1.

Abstract: The present invention provides a plurality of pairs of proximity probes, each pair being capable of binding to a different target analyte, wherein the first and second proximity probes of each pair of probes comprise universal oligonucleotides conjugated to their analyte binding moieties, and hybridised to the universal oligonucleotides are different tag oligonucleotides comprising universal complement domains common to all tag oligonucleotides and unique domains unique to each tag oligonucleotide, as well as methods for their production.

Abstract: A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells; and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.

Abstract: The invention relates to apolypeptide capable of binding to TGF-? for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-?, wherein said polypeptide is capable of inhibiting the interaction of TGF-? with the receptor CLPTM1.

Abstract: The present invention providesabinding agent capable of binding to the extracellular domain of CLPTM1 for use in the treatment or prevention of a condition which is responsive to, or benefits from, (i) immunosuppression, (ii) the reduction or reversal of one or more pro-inflammatory cytokines or the induction of an anti-inflammatory cytokine), (iii) an increase in insulin sensitivity, or (iv) therapy with GDF15 and/or TGF-? and/or IFN?, wherein said binding agent has an EC 50 value of 1 ?g/ml or less when determined by measuring binding to membrane-permeabilised O-876 cells expressing native CLPTM1 by flow cytometry, and wherein said binding agent is not a natural ligand for CLPTM.

Abstract: The present invention provides a plurality of pairs of proximity probes, each pair being capable of binding to a different target analyte, wherein the first and second proximity probes of each pair of probes comprise universal oligonucleotides conjugated to their analyte binding moieties, and hybridised to the universal oligonucleotides are different tag oligonucleotides comprising universal complement domains common to all tag oligonucleotides and unique domains unique to each tag oligonucleotide, as well as methods for their production.

Abstract: The present invention relates to agents for reducing the activity of GDF15 and in particular the use of such agents to treat or prevent conditions associated with elevated or unwanted levels of GDF15. The invention is based on the discovery that GDF15 binds to the receptors CLPTM1 and QRFPR and provides agents for such use in the form of binding agents capable of binding to the receptors and inhibiting the interaction between GDF15 and the receptor. Further agents include polypeptides derived from the receptors which are capable of binding to GDF15 and inhibiting its interaction with the receptors. Also provided are diagnostic methods based on detecting the interaction or an effect thereof, and cytotoxic immune cells modified to have a reduced level and/or activity of CLPTM1.

Abstract: A method of assisting an administrator in the management of users of a health and wellness system is disclosed. Input data is received from client devices of users of the health and wellness system. Levels of progress of each of the users toward meeting their health goals is determined based on the input data. Recommendations of actions for an administrator to perform are generated based on the determined levels of progress. The recommendations of the actions are ranked based on importance measurements associated with the recommendations. For each of the recommendations of the actions, if a confidence measurement corresponding to the importance measurement of the recommendation transgresses a confidence threshold, the recommendation is automatically processed on behalf of the administrator.

Abstract: A pneumatic tire includes a carcass reinforced by a carcass ply extending from a first bead to a second bead, and a single reinforcement disposed radially outward of the carcass ply in a crown portion of the pneumatic tire. The single reinforcement is disposed radially outward of the carcass ply in a crown portion of the pneumatic tire. The single reinforcement includes woven strips reinforced with steel cords. The strips are a constant width of 3.0 mm to 30.0 mm.

Abstract: A pneumatic tire includes a carcass reinforced by a carcass ply extending from a first bead to a second bead, and a single reinforcement disposed radially outward of the carcass ply in a crown portion of the pneumatic tire. The single reinforcement includes a continuous cord forming a generally zig zag pattern across the width of the crown portion. The continuous cord is part of a continuous strip with a constant width of 3.0 mm to 30.0 mm.

Abstract: Methods and compositions for performing low background multiplex nucleic acid amplification reactions are provided. Aspects of the invention include contacting a nucleic acid sample with two or more primer pairs for two or more target nucleic acids under template dependent primer extension reaction conditions, e.g., polymerase chain reaction (PCR) conditions. The resultant amplified composition is then contacted with target nucleic acid circularizing reagents, and product circularized target nucleic acids are then selected, e.g., for further amplification. Also provided are systems and kits that find use in practicing embodiments of the inventions.

Abstract: Methods and compositions for performing low background multiplex nucleic acid amplification reactions are provided. Aspects of the invention include contacting a nucleic acid sample with two or more primer pairs for two or more target nucleic acids under template dependent primer extension reaction conditions, e.g., polymerase chain reaction (PCR) conditions. The resultant amplified composition is then contacted with target nucleic acid circularizing reagents, and product circularized target nucleic acids are then selected, e.g., for further amplification. Also provided are systems and kits that find use in practicing embodiments of the inventions.

Abstract: A common platform computer-based method for repurposing an ontology, comprising the steps of creating an ontology mapping protocol, building a mapping tool based upon the ontology mapping protocol, mapping the ontology onto the common platform using the mapping tool, and, repurposing the ontology based upon the mapping.

Abstract: A common platform computer-based method for repurposing an ontology, comprising the steps of creating an ontology mapping protocol, building a mapping tool based upon the ontology mapping protocol, mapping the ontology onto the common platform using the mapping tool, and, repurposing the ontology based upon the mapping.